Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × Capsules × Plasma cell × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Solitary Fibrous Tumors 1 Sarcoma 1 Recurrence 1 Neoplasm Metastasis 1 Multiple Myeloma 1 Lymphoma, Large-Cell, Anaplastic 1 Lymphoma 1 Granuloma, Plasma Cell 1 Glioma 1 Glioblastoma 1

Interventions

Dexamethasone 93 Cyclophosphamide 48 pomalidomide 44 Bortezomib 33 Lenalidomide 30 fludarabine phosphate 27 carfilzomib 24 Peripheral Blood Stem Cell Transplantation 22 Mycophenolic Acid 22 Calcium Dobesilate 21 daratumumab 19 Cyclosporine 19 Busulfan 18 Antilymphocyte Serum 17 Tacrolimus 16 Whole-Body Irradiation 15 Radiotherapy 15 Melphalan 15 Filgrastim 15 Methotrexate 12 fludarabine 11 Methylprednisolone 10 Cord Blood Stem Cell Transplantation 10 selinexor 9 elotuzumab 9 ixazomib 7 Prednisone 7 Etoposide 7 Thalidomide 6 Panobinostat 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02756663 2016-11-08

PANORAMA-5

Novartis

Phase 2 Withdrawn

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡